<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923063</url>
  </required_header>
  <id_info>
    <org_study_id>1343904</org_study_id>
    <nct_id>NCT02923063</nct_id>
  </id_info>
  <brief_title>Exercise Study Testing Enhanced Energetics of Muscle Mitochondria Video Video Integrated Delivery of Activity Training in CKD</brief_title>
  <acronym>ESTEEM-VIDACKD</acronym>
  <official_title>A Randomized, Controlled Trial of Combined Aerobic and Resistance Exercise on Muscle Mitochondrial Function and Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skeletal muscle dysfunction (sarcopenia) is an under-recognized target organ complication of&#xD;
      CKD with substantial adverse clinical consequences of disability, hospitalization, and death.&#xD;
      Sarcopenia in this proposal is defined by impaired metabolism and physical function&#xD;
      associated with decreased skeletal muscle mass or function. Skeletal muscle tissue relies on&#xD;
      mitochondria to efficiently utilize oxygen to generate ATP. Impaired mitochondrial energetics&#xD;
      is a central mechanism of sarcopenia in CKD. The investigators propose a series of studies&#xD;
      designed to shed light on the pathophysiology of sarcopenia in persons with CKD not treated&#xD;
      with dialysis. Investigators will conduct a randomized-controlled intervention trial of&#xD;
      combined resistance training and aerobic exercise vs. health education to assess changes in&#xD;
      skeletal muscle mitochondrial function, metabolism and physical function. Investigators&#xD;
      hypothesize that exercise improves mitochondrial function and physical function in persons&#xD;
      with CKD. If successful, these experiments will identify novel pathophysiologic mechanisms&#xD;
      for CKD-associated sarcopenia. The proposed study will provide useful insight into benefits&#xD;
      associated with exercise among patients with CKD and investigate mechanisms associated with&#xD;
      improved metabolism, muscle function and physical function in population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcopenia is a common complication of chronic kidney disease. Sarcopenia is defined by&#xD;
      decreased muscle mass or function and is central to the frailty phenotype that is associated&#xD;
      disability, hospitalization, and death. Sarcopenia is a common and devastating complication&#xD;
      of chronic kidney disease (CKD). The investigators and others have demonstrated a high&#xD;
      prevalence of physical frailty among CKD patients not treated with dialysis. Furthermore the&#xD;
      investigators have demonstrated greater than 30% impairment in lower extremity physical&#xD;
      performance measures in persons with CKD compared with predicted values. The aging&#xD;
      demographic among CKD patients will result in a substantial U.S. public health burden&#xD;
      attributable to sarcopenia. In the year 2000, direct healthcare costs attributable to&#xD;
      sarcopenia in the U.S. were18.5 billion.&#xD;
&#xD;
      Sarcopenia is associated with adverse health-related outcomes. Sarcopenia in older adults is&#xD;
      consistently linked with decreased physical functioning, disability, falls, hospitalization,&#xD;
      and mortality. Impaired lower extremity physical performance, as measured by objective&#xD;
      testing, is associated with all-cause mortality in CKD patients not treated with dialysis and&#xD;
      that these associations are stronger in magnitude than those for traditional risk factors.&#xD;
      Skeletal muscle is major site of peripheral glucose utilization ameliorating oxidative stress&#xD;
      and endothelial injury associated with acute post-prandial hyperglycemia. Through these&#xD;
      mechanisms sarcopenia may contribute to metabolic disturbances of insulin resistance,&#xD;
      oxidative stress, and endothelial dysfunction leading to cardiovascular disease.&#xD;
&#xD;
      Mitochondrial dysfunction is central to skeletal muscle dysfunction. Skeletal muscle&#xD;
      mitochondria are necessary for the efficient generation of energy (ATP) from oxygen and&#xD;
      normal lipid metabolism. Under normal conditions, muscle efficiently utilizes the majority of&#xD;
      supplied oxygen such that only 0.2% of mitochondrial oxygen is shuttled into reactive&#xD;
      oxidative species (ROS). Under pathologic situations there is uncoupling of oxygen&#xD;
      consumption and ATP generation resulting in increased oxygen consumption and decreased ATP&#xD;
      production in a process leading to increased ROS and oxidative stress. Uncoupling of oxygen&#xD;
      and ATP generation directly affects skeletal muscle function. Decreased efficiency of ATP&#xD;
      generation has been linked to decreased muscle strength and more recently associated with&#xD;
      decreased gait speed in older adults.&#xD;
&#xD;
      Magnetic resonance spectroscopy and optical spectroscopy (MRS/OS) provide novel, non-invasive&#xD;
      and real-time insight into human skeletal muscle mitochondrial function. MRS/OS is a novel&#xD;
      technique that measures maximal mitochondrial ATP production in-vivo following acute bouts of&#xD;
      ischemia induced by exercise using phosphorous MRS (31P MRS). The rate of recovery of&#xD;
      phosphocreatinine after cessation of exercise is used to characterize the rate of aerobic&#xD;
      mitochondrial ATP resynthesis above that of basal anaerobic glycolytic ATP production. By&#xD;
      combining this technique with optical spectroscopy post-exercise measuring the transport of&#xD;
      oxygen from hemoglobin to myoglobin within the muscle the investigators are able to&#xD;
      accurately determine the ratio of coupling efficiency between of ATP generation per unit of&#xD;
      oxygen consumption. Skeletal muscle mitochondrial dysfunction measured by ATP generating&#xD;
      capacity and coupling efficiency has been associated with processes of aging and insulin&#xD;
      resistance. Furthermore studies in healthy subjects have shown that muscle performance and&#xD;
      fatigue are linked to the ability to resynthesize ATP rather than lactate concentration.&#xD;
&#xD;
      Preliminary MRS/OS findings suggest profoundly altered mitochondrial function in CKD&#xD;
      patients. Previous experimental studies suggest that uremia in dialysis patients affects&#xD;
      skeletal muscle structure and mitochondrial function. Oxidative damage is highly prevalent in&#xD;
      CKD, evidenced by increased biomarkers of oxidative stress and changes in glutathione, an&#xD;
      important antioxidant. Prior small studies in non-diabetic CKD patients suggest impairment of&#xD;
      ex-vivo mitochondrial function by reductions in mitochondrial enzyme activity. Based on these&#xD;
      findings investigators used novel, non-invasive, functional MRS/OS assay to characterize&#xD;
      in-vivo mitochondrial function. Preliminary findings in non-diabetic CKD patients indicate&#xD;
      markedly reduced ATP to oxygen ratio compared to controls. This finding suggests altered&#xD;
      mitochondrial energetics as a candidate central mechanism linking metabolic derangements and&#xD;
      impaired physical function in CKD, and motivate the hypothesis that mitochondrial dysfunction&#xD;
      is associated with oxidative stress, insulin resistance and impaired physical functioning in&#xD;
      CKD.&#xD;
&#xD;
      Exercise may ameliorate mitochondrial dysfunction, insulin resistance and physical&#xD;
      functioning in CKD. Studies of exercise in non-CKD patients with diabetes and insulin&#xD;
      resistance have demonstrated exercise-induced improvements in mitochondrial biogenesis linked&#xD;
      to improved insulin sensitivity as well as decreased mitochondrial oxidative stress. Animal&#xD;
      studies suggest that exercise stimulates autophagy resulting in removal of defective and&#xD;
      inefficient mitochondrial leading to a healthy mitochondrial network and improved insulin&#xD;
      sensitivity.The primary goal of this study is to investigate the impact of combined&#xD;
      resistance and aerobic exercise on skeletal muscle dysfunction. Given the investigator's&#xD;
      preliminary data demonstrating strong association of sarcopenia and mortality in CKD,&#xD;
      effective interventions that can impact physical function are urgently needed to improve&#xD;
      patient health outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial phosphorylation capacity (ATPmax) by in-vivo 31P MRS</measure>
    <time_frame>12 weeks</time_frame>
    <description>leg muscles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quadriceps muscle work efficiency</measure>
    <time_frame>12 weeks</time_frame>
    <description>Work efficiency calculated by cycler ergometry VO2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in physical performance</measure>
    <time_frame>12 weeks</time_frame>
    <description>6 minute walking distance (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic oxidative stress (markers of arachidonic acid peroxidation)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma isofurans (pg/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aerobic capacity (VO2max) (ml/kg/min)</measure>
    <time_frame>12 weeks</time_frame>
    <description>mM (millimole)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte bioenergetics</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reserve Capacity (pmo/min/mcg protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle fatigue</measure>
    <time_frame>12 weeks</time_frame>
    <description>Force-time integral using biodex in isometric mode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mitochondrial reactive oxygen species production from permeabilized muscle fibers.</measure>
    <time_frame>12 weeks</time_frame>
    <description>hydrogen peroxide (H2O2) production (pmol/min/mg protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported fatigue (NIH PROMIS Fatigue)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self reported fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported physical function (PROMIS mobility)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self reported difficulty with mobility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MoCA test (cognitive testing)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported cognitive testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connor-Davidson Resilience Scale 25 (CD-RISC-25)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported cognitive testing (depression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported personal health history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACIT fatigue scale (Version 4)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported fatigue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Questionnaire (HAP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self reported activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lubben Social Network Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported social engagement questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Fatigability Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported fatigability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Efficacy for Managing Chronic Conditions (PROMIS Bank)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported Managing Symptoms, Managing Emotions, Managing Medications and Treatment, Managing Social Interactions, Managing Daily Activities, Cognitive Function, and Profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Disease and Quality of Life (KDQOL-SFâ„¢ 1.3)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported kidney health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress (NIH)</measure>
    <time_frame>12 weeks</time_frame>
    <description>self reported perceived stress</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Walking economy during 6 minute walk</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessement of energetic cost of walking during a submaximal 6 minute walk test using COSMED</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Moderate-severe Chronic Kidney Disease Not Treated With Dialysis</condition>
  <condition>Diabetic Kidney Disease, HgbA1c Less Than 8.5</condition>
  <arm_group>
    <arm_group_label>Combined Aerobic and Resistance Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise will be supervised by exercise trainers 3 days per week for 12 weeks via videoconferencing. Aerobic intervention sessions of 30-minute duration will target 60-80% of the maximal heart rate (or rating of perceived exertion of 13 on a scale of 6-20). We will encourage adherence to 50% ambulatory based and 50% cycling based aerobic exercise each session targeting the same goal heart rate.&#xD;
Resistance exercises occur 3 times weekly. The load will be adjusted for each exercise as needed on successive sets to ensure that subjects achieved momentary failure in the target repetition range. The load will be increased based on the supervising researcher's assessment of what would be required to reach momentary failure in the desired loading range; if less than 8 repetitions were accomplished, the load was similarly decreased. All routines will be directly supervised by the research team to ensure proper performance of the respective routines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a &quot;Go4Life Workout to go&quot; sample exercise routing created by the national institutes on aging (NIA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Combined Aerobic and Resistance Exercise via videoconferencing</intervention_name>
    <description>Combined aerobic and resistance exercise session thrice weekly for 12 weeks</description>
    <arm_group_label>Combined Aerobic and Resistance Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate-severe CKD determined by estimated glomerular filtration rate (eGFR)&#xD;
             &lt;60ml/min per 1.73m2&#xD;
&#xD;
          -  No history chronic treatment with dialysis.&#xD;
&#xD;
          -  Age 30 years old to 75 years&#xD;
&#xD;
          -  Sedentary defined as self-reporting no more than 1 day per week of regular&#xD;
             (structured) endurance exercise (EE) [e.g., brisk walking, jogging/running, cycling,&#xD;
             elliptical, or swimming activity that results in feelings of increased heart rate or&#xD;
             rapid breathing (EE), and/or sweating] or resistance exercise (RE) (resulting in&#xD;
             muscular fatigue) lasting no more than 60 minutes in the past year.&#xD;
&#xD;
               -  Persons bicycling as a mode of transportation to/from work &gt; 1 day/week etc. are&#xD;
                  not considered sedentary&#xD;
&#xD;
               -  Leisure walkers are included unless they meet the heart rate, breathing and&#xD;
                  sweating criteria noted above&#xD;
&#xD;
               -  Persons adherent to both 1 day/week of RE and 1 day/week of EE are excluded&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or previous transplantation&#xD;
&#xD;
          -  Current pregnancy (all females of child-bearing potential will have a pregnancy test)&#xD;
&#xD;
          -  Wheelchair dependence or other disability that precludes physical exercise&#xD;
&#xD;
          -  Oxygen dependent Chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Shortness of breath after walking &lt;100 steps on flat surface&#xD;
&#xD;
          -  Weight &gt;300 pounds&#xD;
&#xD;
          -  HIV infection or hepatitis viral infection&#xD;
&#xD;
          -  Decompensated cirrhosis&#xD;
&#xD;
          -  Active malignant cancer other than non-melanomatous skin cancer&#xD;
&#xD;
          -  Drugs that alter mitochondrial function:&#xD;
&#xD;
               -  muscle relaxants (methocarbamol, baclofen, tizanidine, carisoprodol,&#xD;
                  cyclobenzaprine)&#xD;
&#xD;
               -  oral steroids (Equivalent of 10mg or more of prednisone daily)&#xD;
&#xD;
               -  anti-viral medications (tenofovir, zalcitabine, didanosine, stavudine,&#xD;
                  lamivudine, zidovudine, abacavir, adefovir, interferon, ribavirin, efavirenz,&#xD;
                  dasabuvir, ombitasvir)&#xD;
&#xD;
               -  oral calcineurin inhibitors (Tacrolimus, Cyclosporine)&#xD;
&#xD;
               -  Antiepileptic drugs (Phenytoin, phenobarbital, carbamazepine, valproic acid,&#xD;
                  oxcarbazepine, ethosuximide, zonisamide, topiramate, and vigabatrin)&#xD;
&#xD;
               -  Antipsychotics (haloperidol, thioridazine, risperidone, quetiapine, clozapine,&#xD;
                  olanzapine and aripiprazole)&#xD;
&#xD;
          -  Drugs- anticoagulants or antiplatelets&#xD;
&#xD;
               -  Anticoagulants, any 1 (coumadin, rivaroxaban, apixaban, dabigatran, edoxaban)&#xD;
&#xD;
               -  Antiplatelets, any 2 (aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel,&#xD;
                  ticagrelor, ticlopidine, vorapaxar)&#xD;
&#xD;
          -  Implants that prohibit MRI measurements or trauma involving metal fragments&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  History of clotting disorder (Deep venous thrombosis, pulmonary embolism) or bleeding&#xD;
             disorder.&#xD;
&#xD;
          -  History of sever heart disease/disorders: coronary artery bypass graft (CABG) surgery,&#xD;
             atrial fibrillation&#xD;
&#xD;
          -  Vascular stent: bare metal or any recently placed (within 6 months)&#xD;
&#xD;
          -  Current substance abuse&#xD;
&#xD;
          -  Institutionalization&#xD;
&#xD;
          -  Current participation in an interventional trial&#xD;
&#xD;
          -  Inability to provide informed consent without a proxy respondent&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Any condition which in the judgement of the clinical investigator places the&#xD;
             participant at risk from participation in the study.&#xD;
&#xD;
        Additional Criteria:&#xD;
&#xD;
          -  On chronic dialysis&#xD;
&#xD;
          -  Expectation to start dialysis within 6 months.&#xD;
&#xD;
          -  High dose antioxidants (Vitamine C, Vitamin E)&#xD;
&#xD;
          -  Baseline systolic blood pressure &gt;170 or diastolic blood pressure &gt;100&#xD;
&#xD;
          -  Uncontrolled diabetes with a HgbA1c &gt;8.5&#xD;
&#xD;
          -  Active uncontrolled thyroid disease&#xD;
&#xD;
          -  Anemia (Hgb &lt;9 g/dL)&#xD;
&#xD;
          -  Current substance abuse (i.e. amphetamine abuse)&#xD;
&#xD;
          -  Chronic opioid use (i.e. for chronic pain)&#xD;
&#xD;
          -  Chronic use of immunosuppressants&#xD;
&#xD;
          -  Active coronary ischemia detected by ECG on cycle ergometry VO2max testing. These&#xD;
             individuals will be promptly referred to their primary care provider by the PI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baback Roshanravan, MD MS MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Lopez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis Department of Medicine/Division of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baback Roshanravan, MD MS MSPH</last_name>
    <phone>5307540893</phone>
    <email>broshanr@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Roshanravan, MD MS MSPH</last_name>
      <phone>530-754-0893</phone>
      <email>broshanr@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Baback Roshanravan, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Henricson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Mitochondrial Metabolism</keyword>
  <keyword>Physical Performance</keyword>
  <keyword>Exercise Intolerance</keyword>
  <keyword>Muscle Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

